Published in Clin Cancer Res on November 24, 2009
Oncolytic virotherapy. Nat Biotechnol (2012) 5.79
Concise review: Dissecting a discrepancy in the literature: do mesenchymal stem cells support or suppress tumor growth? Stem Cells (2011) 2.74
Oncolytic viruses: a new class of immunotherapy drugs. Nat Rev Drug Discov (2015) 1.47
Cancer nanotheranostics: improving imaging and therapy by targeted delivery across biological barriers. Adv Mater (2011) 1.33
Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions. Future Microbiol (2012) 1.28
A comparative study of neural and mesenchymal stem cell-based carriers for oncolytic adenovirus in a model of malignant glioma. Mol Pharm (2011) 1.27
Oncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancer. Cancer Res (2014) 1.20
Optimizing patient derived mesenchymal stem cells as virus carriers for a phase I clinical trial in ovarian cancer. J Transl Med (2013) 1.16
The use of neural stem cells in cancer gene therapy: predicting the path to the clinic. Curr Opin Mol Ther (2010) 1.15
To grab the stroma by the horns: from biology to cancer therapy with mesenchymal stem cells. Oncotarget (2013) 1.05
Treatment of medulloblastoma with a modified measles virus. Neuro Oncol (2010) 0.99
Molecular imaging for assessment of mesenchymal stem cells mediated breast cancer therapy. Biomaterials (2014) 0.96
Envelope-chimeric entry-targeted measles virus escapes neutralization and achieves oncolysis. Mol Ther (2011) 0.96
Mesenchymal stem cells as a vector for the inflammatory prostate microenvironment. Endocr Relat Cancer (2013) 0.96
Oncolytic measles virus strains as novel anticancer agents. Expert Opin Biol Ther (2013) 0.95
Attenuated oncolytic measles virus strains as cancer therapeutics. Curr Pharm Biotechnol (2012) 0.93
Oncolytic measles virus prolongs survival in a murine model of cerebral spinal fluid-disseminated medulloblastoma. Neuro Oncol (2012) 0.91
Antitumor Virotherapy by Attenuated Measles Virus (MV). Biology (Basel) (2013) 0.91
Lymphokine-activated killer and dendritic cell carriage enhances oncolytic reovirus therapy for ovarian cancer by overcoming antibody neutralization in ascites. Int J Cancer (2013) 0.90
Systemically delivered measles virus-infected mesenchymal stem cells can evade host immunity to inhibit liver cancer growth. J Hepatol (2013) 0.89
A specific subpopulation of mesenchymal stromal cell carriers overrides melanoma resistance to an oncolytic adenovirus. Stem Cells Dev (2012) 0.85
Carrier cell-based delivery of replication-competent HSV-1 mutants enhances antitumor effect for ovarian cancer. Cancer Gene Ther (2010) 0.85
Enhancing cytokine-induced killer cell therapy of multiple myeloma. Exp Hematol (2013) 0.84
Crossing the boundaries: stem cells and gene therapy. Discov Med (2010) 0.83
Oncolytic vaccinia virotherapy for endometrial cancer. Gynecol Oncol (2014) 0.82
Polyinosinic acid decreases sequestration and improves systemic therapy of measles virus. Cancer Gene Ther (2011) 0.82
Oncolytic Viruses to Treat Ovarian Cancer Patients - a Review of Results From Clinical Trials. Geburtshilfe Frauenheilkd (2012) 0.80
Antiglioma oncolytic virotherapy: unattainable goal or a success story in the making? Future Virol (2013) 0.79
Close interactions between mesenchymal stem cells and neuroblastoma cell lines lead to tumor growth inhibition. PLoS One (2012) 0.79
Measles to the Rescue: A Review of Oncolytic Measles Virus. Viruses (2016) 0.79
Stem Cell-Based Cell Carrier for Targeted Oncolytic Virotherapy: Translational Opportunity and Open Questions. Viruses (2015) 0.78
Myeloma xenograft destruction by a nonviral vector delivering oncolytic infectious nucleic acid. Mol Ther (2011) 0.78
Measles Edmonston vaccine strain derivatives have potent oncolytic activity against osteosarcoma. Cancer Gene Ther (2014) 0.77
Oncolytic measles virus efficacy in murine xenograft models of atypical teratoid rhabdoid tumors. Neuro Oncol (2015) 0.77
Assessment of current virotherapeutic application schemes: "hit hard and early" versus "killing softly"? Mol Ther Oncolytics (2015) 0.77
MMP14 as a novel downstream target of VEGFR2 in migratory glioma-tropic neural stem cells. Stem Cell Res (2015) 0.77
Oncolytic virotherapy for ovarian cancer. Oncolytic Virother (2012) 0.77
Clinical Trials with Oncolytic Measles Virus: Current Status and Future Prospects. Curr Cancer Drug Targets (2017) 0.76
Polymeric oncolytic adenovirus for cancer gene therapy. J Control Release (2015) 0.76
A novel, polymer-coated oncolytic measles virus overcomes immune suppression and induces robust antitumor activity. Mol Ther Oncolytics (2016) 0.75
Cell carriers for oncolytic viruses: current challenges and future directions. Oncolytic Virother (2013) 0.75
Advances in the design and development of oncolytic measles viruses. Oncolytic Virother (2015) 0.75
Biosafety considerations for attenuated measles virus vectors used in virotherapy and vaccination. Hum Vaccin Immunother (2015) 0.75
Characterization of the Tumor Microenvironment and Tumor-Stroma Interaction by Non-invasive Preclinical Imaging. Front Oncol (2017) 0.75
Oncolytic Virotherapy: A Contest between Apples and Oranges. Mol Ther (2017) 0.75
Mesenchymal stromal cells for the delivery of oncolytic viruses in gliomas. Cytotherapy (2017) 0.75
Potential and clinical translation of oncolytic measles viruses. Expert Opin Biol Ther (2017) 0.75
Patient-derived mesenchymal stem cells as delivery vehicles for oncolytic virotherapy: novel state-of-the-art technology. Oncolytic Virother (2015) 0.75
Oncolytic Viruses-Interaction of Virus and Tumor Cells in the Battle to Eliminate Cancer. Front Oncol (2017) 0.75
Exploiting homing abilities of cell carriers: Targeted delivery of nanoparticles for cancer therapy. Biochem Pharmacol (2017) 0.75
Oncolytic Adenovirus-Loaded Menstrual Blood Stem Cells Overcome the Blockade of Viral Activity Exerted by Ovarian Cancer Ascites. Mol Ther Oncolytics (2017) 0.75
Immune System, Friend or Foe of Oncolytic Virotherapy? Front Oncol (2017) 0.75
Oncolytic Viruses-Natural and Genetically Engineered Cancer Immunotherapies. Front Oncol (2017) 0.75
Genetically engineered suicide gene in mesenchymal stem cells using a Tet-On system for anaplastic thyroid cancer. PLoS One (2017) 0.75
Fighting Cancer with Mathematics and Viruses. Viruses (2017) 0.75
Cancer statistics, 2008. CA Cancer J Clin (2008) 86.74
Codon-optimized Gaussia luciferase cDNA for mammalian gene expression in culture and in vivo. Mol Ther (2005) 6.04
Mesenchymal stem cell homing: the devil is in the details. Cell Stem Cell (2009) 4.75
From the laboratory bench to the patient's bedside: an update on clinical trials with mesenchymal stem cells. J Cell Physiol (2007) 3.87
Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses. Proc Natl Acad Sci U S A (2006) 2.72
Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter. Blood (2003) 2.67
Inflammation and tumor microenvironments: defining the migratory itinerary of mesenchymal stem cells. Gene Ther (2008) 2.50
Synergistic antitumor effects of immune cell-viral biotherapy. Science (2006) 2.37
Intraperitoneal therapy of ovarian cancer using an engineered measles virus. Cancer Res (2002) 2.18
High CD46 receptor density determines preferential killing of tumor cells by oncolytic measles virus. Cancer Res (2004) 2.14
Carrier cell-based delivery of an oncolytic virus circumvents antiviral immunity. Mol Ther (2007) 1.93
Mesenchymal progenitor cells as cellular vehicles for delivery of oncolytic adenoviruses. Mol Cancer Ther (2006) 1.88
Recent advances into the understanding of mesenchymal stem cell trafficking. Br J Haematol (2007) 1.84
Systemic therapy of myeloma xenografts by an attenuated measles virus. Blood (2001) 1.84
Non-invasive in vivo monitoring of trackable viruses expressing soluble marker peptides. Nat Med (2002) 1.80
Early detection of ovarian cancer. Dis Markers (2007) 1.77
Mesenchymal stem cells effectively deliver an oncolytic adenovirus to intracranial glioma. Stem Cells (2008) 1.74
Mutant torsinA interferes with protein processing through the secretory pathway in DYT1 dystonia cells. Proc Natl Acad Sci U S A (2007) 1.73
Viruses as anticancer drugs. Trends Pharmacol Sci (2007) 1.63
The role of the diaphragm in lymphatic absorption from the peritoneal cavity. J Anat (1995) 1.62
Optimal chemotherapy treatment for women with recurrent ovarian cancer. Curr Oncol (2007) 1.55
The (in) auspicious role of mesenchymal stromal cells in cancer: be it friend or foe. Cytotherapy (2008) 1.52
Infected cell carriers: a new strategy for systemic delivery of oncolytic measles viruses in cancer virotherapy. Mol Ther (2007) 1.46
Complement-regulatory proteins in ovarian malignancies. Int J Cancer (1997) 1.44
Evaluation of T cells as carriers for systemic measles virotherapy in the presence of antiviral antibodies. Gene Ther (2006) 1.43
Oncolytic measles virus targets high CD46 expression on multiple myeloma cells. Exp Hematol (2006) 1.42
The host response to cancer virotherapy. Curr Opin Mol Ther (2008) 1.36
Loading of oncolytic vesicular stomatitis virus onto antigen-specific T cells enhances the efficacy of adoptive T-cell therapy of tumors. Gene Ther (2008) 1.34
Cellular composition of milky spots in the human greater omentum: an immunochemical and ultrastructural study. Anat Rec (1995) 1.23
Cell-based delivery of oncolytic viruses: a new strategic alliance for a biological strike against cancer. Mol Ther (2007) 1.22
Human mesenchymal stem cells lack tumor tropism but enhance the antitumor activity of oncolytic adenoviruses in orthotopic lung and breast tumors. Hum Gene Ther (2007) 1.19
Immunotherapy opportunities in ovarian cancer. Expert Rev Anticancer Ther (2008) 1.18
Use of carrier cells to deliver a replication-selective herpes simplex virus-1 mutant for the intraperitoneal therapy of epithelial ovarian cancer. Clin Cancer Res (1999) 1.11
Integrating the biological characteristics of oncolytic viruses and immune cells can optimize therapeutic benefits of cell-based delivery. Gene Ther (2008) 1.10
Tumor-associated macrophages infiltrate plasmacytomas and can serve as cell carriers for oncolytic measles virotherapy of disseminated myeloma. Am J Hematol (2009) 1.08
Gene therapy for ovarian cancer. Curr Oncol Rep (2006) 1.08
Combined oncolytic and vaccination activities of parvovirus H-1 in a metastatic tumor model. Oncol Rep (2007) 1.06
Oncolytic activities of approved mumps and measles vaccines for therapy of ovarian cancer. Cancer Gene Ther (2005) 1.03
Carrier cell-mediated delivery of a replication-competent adenovirus for cancer gene therapy. Mol Ther (2007) 0.99
Carrier cell-mediated delivery of oncolytic parvoviruses for targeting metastases. Int J Cancer (2004) 0.99
Restriction of measles virus RNA synthesis by a mouse host cell line: trans-complementation by polymerase components or a human cellular factor(s). J Virol (2002) 0.98
Novel therapeutic agents in ovarian cancer. Eur J Surg Oncol (2006) 0.98
In vivo traffic of indium-111-oxine labeled human lymphocytes collected by automated apheresis. J Nucl Med (1990) 0.95
Role of milky spots as selective implantation sites for malignant cells in peritoneal dissemination in mice. J Cancer Res Clin Oncol (1996) 0.95
Metastatic pattern of CC531 colon carcinoma cells in the abdominal cavity: an experimental model of peritoneal carcinomatosis in rats. Eur J Surg Oncol (2001) 0.94
CD46 expression does not overcome the intracellular block of measles virus replication in transgenic rats. J Virol (1997) 0.92
Post-capillary venules in the "milky spots" of the greater omentum are the major site of plasma protein and leukocyte extravasation in rodent models of peritonitis. Inflamm Res (1995) 0.92
The utility of cells as vehicles for oncolytic virus therapies. Curr Opin Mol Ther (2008) 0.90
Targeted gene therapy for ovarian cancer. Curr Gene Ther (2005) 0.89
Bevacizumab in the treatment of ovarian cancer. Expert Rev Anticancer Ther (2007) 0.83
Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol (2010) 14.79
Improved survival in multiple myeloma and the impact of novel therapies. Blood (2007) 12.70
Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood (2005) 5.82
Oncolytic virotherapy. Nat Biotechnol (2012) 5.79
Patient tumor EGFR and PDGFRA gene amplifications retained in an invasive intracranial xenograft model of glioblastoma multiforme. Neuro Oncol (2005) 4.10
Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress. Nat Clin Pract Oncol (2007) 3.86
Adductor canal block versus femoral nerve block for total knee arthroplasty: a prospective, randomized, controlled trial. Anesthesiology (2014) 3.80
Engineering targeted viral vectors for gene therapy. Nat Rev Genet (2007) 3.69
Quantum-sized carbon dots for bright and colorful photoluminescence. J Am Chem Soc (2006) 3.08
Identification of molecular characteristics correlated with glioblastoma sensitivity to EGFR kinase inhibition through use of an intracranial xenograft test panel. Mol Cancer Ther (2007) 2.89
Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma. Mayo Clin Proc (2006) 2.88
Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines. Mayo Clin Proc (2009) 2.86
Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter. Blood (2003) 2.67
Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. Mayo Clin Proc (2013) 2.59
Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement. Mayo Clin Proc (2007) 2.55
History of oncolytic viruses: genesis to genetic engineering. Mol Ther (2007) 2.51
Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. J Clin Oncol (2009) 2.50
Exome sequencing identifies truncating mutations in PRRT2 that cause paroxysmal kinesigenic dyskinesia. Nat Genet (2011) 2.48
Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease. Blood (2011) 2.45
Targeting angiogenesis: progress with anti-VEGF treatment with large molecules. Nat Rev Clin Oncol (2009) 2.41
Rescue and propagation of fully retargeted oncolytic measles viruses. Nat Biotechnol (2005) 2.40
Immunosuppressive CD14+HLA-DR(low)/- monocytes in B-cell non-Hodgkin lymphoma. Blood (2010) 2.38
Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma. Mayo Clin Proc (2007) 2.34
Immunosuppressive CD14+HLA-DRlow/- monocytes in prostate cancer. Prostate (2010) 2.22
Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer. Cancer Res (2010) 2.19
Intraperitoneal therapy of ovarian cancer using an engineered measles virus. Cancer Res (2002) 2.18
Engineering microRNA responsiveness to decrease virus pathogenicity. Nat Med (2008) 2.14
High CD46 receptor density determines preferential killing of tumor cells by oncolytic measles virus. Cancer Res (2004) 2.14
Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients. Blood (2009) 2.12
Use of a vaccine strain of measles virus genetically engineered to produce carcinoembryonic antigen as a novel therapeutic agent against glioblastoma multiforme. Cancer Res (2003) 2.12
Functionalized carbon nanotubes: properties and applications. Acc Chem Res (2002) 2.03
Importance of achieving stringent complete response after autologous stem-cell transplantation in multiple myeloma. J Clin Oncol (2013) 2.01
Circulating MMP2 and MMP9 in breast cancer -- potential role in classification of patients into low risk, high risk, benign disease and breast cancer categories. Int J Cancer (2006) 2.00
Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative component. Mayo Clin Proc (2009) 1.96
The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis. Blood (2006) 1.94
Redefining the Ideal Buttocks: A Population Analysis. Plast Reconstr Surg (2016) 1.92
Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics. Blood (2012) 1.91
Carbon dots for multiphoton bioimaging. J Am Chem Soc (2007) 1.89
Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol (2012) 1.87
Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone. Blood (2009) 1.86
Normal human monocytes exposed to glioma cells acquire myeloid-derived suppressor cell-like properties. Neuro Oncol (2009) 1.80
Non-invasive in vivo monitoring of trackable viruses expressing soluble marker peptides. Nat Med (2002) 1.80
Smooth muscle cells in human coronary atherosclerosis can originate from cells administered at marrow transplantation. Proc Natl Acad Sci U S A (2003) 1.70
Phenome-wide association study (PheWAS) for detection of pleiotropy within the Population Architecture using Genomics and Epidemiology (PAGE) Network. PLoS Genet (2013) 1.70
Evaluation of the metabochip genotyping array in African Americans and implications for fine mapping of GWAS-identified loci: the PAGE study. PLoS One (2012) 1.65
Viruses as anticancer drugs. Trends Pharmacol Sci (2007) 1.63
TAT-mediated delivery of neuroglobin protects against focal cerebral ischemia in mice. Exp Neurol (2010) 1.62
Characterization of gene-environment interactions for colorectal cancer susceptibility loci. Cancer Res (2012) 1.58
Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis. Clin Cancer Res (2002) 1.57
Trans-ethnic fine-mapping of lipid loci identifies population-specific signals and allelic heterogeneity that increases the trait variance explained. PLoS Genet (2013) 1.57
Clinical outcome of immunoglobulin light chain amyloidosis affecting the kidney. Nephrol Dial Transplant (2009) 1.56
Renal vein cytokine release as an index of renal parenchymal inflammation in chronic experimental renal artery stenosis. Nephrol Dial Transplant (2013) 1.56
Engineering oncolytic viruses to exploit tumor specific defects in innate immune signaling pathways. Expert Opin Biol Ther (2009) 1.54
Phase I and pharmacokinetic study of two different schedules of oxaliplatin, irinotecan, Fluorouracil, and leucovorin in patients with solid tumors. J Clin Oncol (2003) 1.54
Systemic immune suppression in glioblastoma: the interplay between CD14+HLA-DRlo/neg monocytes, tumor factors, and dexamethasone. Neuro Oncol (2010) 1.53
Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score. Mayo Clin Proc (2011) 1.53
High-dose chemotherapy with autologous stem cell transplantation in adults with recurrent embryonal tumors of the central nervous system. Cancer (2008) 1.52
Long-term outcomes of patients with light chain amyloidosis (AL) after renal transplantation with or without stem cell transplantation. Nephrol Dial Transplant (2011) 1.51
The use of a tropism-modified measles virus in folate receptor-targeted virotherapy of ovarian cancer. Clin Cancer Res (2006) 1.50
Protease activity of urokinase and tumor progression in a syngeneic mammary cancer model. J Natl Cancer Inst (2006) 1.49
Dual therapy of ovarian cancer using measles viruses expressing carcinoembryonic antigen and sodium iodide symporter. Clin Cancer Res (2006) 1.47
Attenuation of vesicular stomatitis virus encephalitis through microRNA targeting. J Virol (2009) 1.46
Infected cell carriers: a new strategy for systemic delivery of oncolytic measles viruses in cancer virotherapy. Mol Ther (2007) 1.46
Statins and beta-cell function. Med Sci Monit (2010) 1.46
The utility of plasma vascular endothelial growth factor levels in the diagnosis and follow-up of patients with POEMS syndrome. Blood (2011) 1.46
Vorinostat in solid and hematologic malignancies. J Hematol Oncol (2009) 1.42
Oncolytic measles virus targets high CD46 expression on multiple myeloma cells. Exp Hematol (2006) 1.42
Clinical trial end points for high-grade glioma: the evolving landscape. Neuro Oncol (2011) 1.42
Retargeted oncolytic measles strains entering via the EGFRvIII receptor maintain significant antitumor activity against gliomas with increased tumor specificity. Cancer Res (2006) 1.40
Engineered measles virus as a novel oncolytic viral therapy system for hepatocellular carcinoma. Hepatology (2006) 1.40
Antibody-targeted cell fusion. Nat Biotechnol (2004) 1.39
Clinical testing of engineered oncolytic measles virus strains in the treatment of cancer: an overview. Curr Opin Mol Ther (2009) 1.35
Diversity arrays technology (DArT) for pan-genomic evolutionary studies of non-model organisms. PLoS One (2008) 1.35
Immunoglobulin g antibody-mediated enhancement of measles virus infection can bypass the protective antiviral immune response. J Virol (2006) 1.35
Platelet lysate consisting of a natural repair proteome supports human mesenchymal stem cell proliferation and chromosomal stability. Cell Transplant (2010) 1.34
Long-term cardiac pro-B-type natriuretic peptide gene delivery prevents the development of hypertensive heart disease in spontaneously hypertensive rats. Circulation (2011) 1.33
Diagnosis and management of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines. Mayo Clin Proc (2010) 1.32
Epidermal growth factor receptor (EGFR)-retargeted measles virus strains effectively target EGFR- or EGFRvIII expressing gliomas. Mol Ther (2007) 1.32